Physician profile
Chandra D Mathis
NPI 1548718125
$2,293.16
in general payments reported to CMS, 2019-2025
33 companies · $85.59 in 2025
The $85.59 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.18 · 2022: $1,744 · 2023: $276 · 2024: $106 · 2025: $85.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $270.96 | 2022-2025 | |
| Lilly USA, LLC | $253.09 | 2022-2023 | Verzenio |
| Merck Sharp & Dohme LLC | $178.80 | 2022-2023 | Keytruda |
| Amgen INC. | $158.18 | 2022 | |
| Abbvie INC. | $136.81 | 2022-2025 | |
| Janssen Biotech, INC. | $131.58 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $106.14 | 2022-2023 | Tavalisse, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $97.51 | 2022-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $95.97 | 2022-2023 | Imbruvica, Epkinly |
| Aveo Pharmaceuticals, INC. | $78.49 | 2022 | |
| Seagen INC. | $74.08 | 2021-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $70.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $67.66 | 2022 | |
| Exelixis INC. | $66.68 | 2022 | |
| Glaxosmithkline, LLC. | $58.56 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.33 | 2022 | |
| Eisai INC. | $47.43 | 2022-2023 | |
| Genzyme Corporation | $36.10 | 2022 | |
| Pfizer INC. | $34.16 | 2025 | |
| Array Biopharma INC | $33.79 | 2022-2023 | Xalkori, Lorbrena, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $32.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.59 | 2022 | |
| Gilead Sciences, INC. | $26.84 | 2022 | |
| Celgene Corporation | $18.05 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.24 | 2022 | |
| Cti Biopharma Corp. | $16.85 | 2022 | |
| Incyte Corporation | $16.68 | 2022 | |
| Kyowa Kirin, INC. | $15.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.09 | 2022 | |
| Epizyme, INC. | $13.84 | 2022 | |
| Eagle Pharmaceuticals, INC. | $13.79 | 2022 | |
| Sobi, INC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.